Physician profile
Michael E Krutchik
NPI 1609865161
$7,391.88
in general payments reported to CMS, 2019-2025
31 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $227 · 2021: $414 · 2022: $1,231 · 2023: $1,973 · 2024: $1,649 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,136.48 | 2019-2025 | |
| Epsfl, LLC | $620.77 | 2023 | |
| Sun Pharmaceutical Industries INC. | $602.81 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Ucb, INC. | $566.69 | 2019-2024 | Cimzia, Bimzelx |
| Lilly USA, LLC | $485.11 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $456.26 | 2019-2025 | |
| Galderma Laboratories, L.P. | $456.11 | 2019-2025 | Nemluvio |
| Biofrontera INC. | $389.26 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $376.23 | 2021-2024 | Puraply, Matrix |
| Arcutis Biotherapeutics, INC. | $315.47 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $255.56 | 2021-2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $189.30 | 2019-2022 | |
| Almirall LLC | $185.86 | 2019-2024 | Seysara |
| Incyte Corporation | $145.89 | 2021-2023 | Opzelura |
| Genzyme Corporation | $142.65 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $134.99 | 2020-2024 | Otezla |
| Kerecis Limited | $134.45 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| E.R. Squibb & Sons, L.L.C. | $130.08 | 2024 | Sotyktu |
| Verrica Pharmaceuticals INC. | $124.98 | 2025 | Ycanth |
| Janssen Biotech, INC. | $92.26 | 2019-2024 | Tremfya |
| Leo Pharma INC. | $74.54 | 2024-2025 | Adbry |
| Pfizer INC. | $72.69 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $71.82 | 2021-2022 | |
| Sebela Pharmaceuticals INC. | $46.72 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $46.28 | 2022-2023 | Valchlor |
| Convatec INC. | $37.39 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.77 | 2019 | |
| Paratek Pharmaceuticals, INC. | $23.39 | 2022 | |
| Dusa Pharmaceuticals, INC. | $22.88 | 2019 | |
| Sandoz INC. | $17.22 | 2019 | |
| Encore Dermatology INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Krutchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.